LISATA THERAPEUTICS INC. - COMMON STOCK

2.2800

02-September-25 06:48:31

15 minutes delayed

Stocks

-0.0400

-1.72%

Today's range

2.2501 - 2.3944

ISIN

N/A

Source

NASDAQ

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

02 May 2024 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

23 Apr 2024 04:30:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

09 Apr 2024 05:30:00 By Nasdaq GlobeNewswire
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

03 Apr 2024 05:30:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

21 Mar 2024 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

29 Feb 2024 13:05:00 By Nasdaq GlobeNewswire
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

22 Feb 2024 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics to Present at BIO CEO & Investor Conference

20 Feb 2024 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

17 Jan 2024 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

04 Jan 2024 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

12 Dec 2023 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics to Present at NobleCon19 Investor Conference

28 Nov 2023 13:05:03 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in November

09 Nov 2023 13:05:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

02 Nov 2023 13:05:01 By Nasdaq GlobeNewswire
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

26 Oct 2023 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

24 Oct 2023 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer

17 Oct 2023 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in October

28 Sep 2023 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces Participation in InfoSec World 2023

20 Sep 2023 05:00:00 By Nasdaq GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

12 Sep 2023 05:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.